BioWorld

July 24, 2006

Solid Earnings For Amgen As Aranesp Hits $1B For Quarter

Amgen Inc. soundly beat estimates for the second quarter, led by a boost in product revenue, including a 26 percent increase in sales of the anemia drug Aranesp. (BioWorld Today) Read More

ViroPharma's Generic Fight Takes On FDA Rule Change

Survey Points To PDUFA As Reason For Low FDA Morale

Cleveland BioLabs: $10.2M For Radioprotectant Drugs

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...